245 related articles for article (PubMed ID: 24257427)
1. Cytomegalovirus vaccines.
McVoy MA
Clin Infect Dis; 2013 Dec; 57 Suppl 4(Suppl 4):S196-9. PubMed ID: 24257427
[TBL] [Abstract][Full Text] [Related]
2. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
[TBL] [Abstract][Full Text] [Related]
3. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.
Cui X; Meza BP; Adler SP; McVoy MA
Vaccine; 2008 Oct; 26(45):5760-6. PubMed ID: 18718497
[TBL] [Abstract][Full Text] [Related]
5. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
6. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
7. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E; Plotkin S
Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
[TBL] [Abstract][Full Text] [Related]
8. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
Wussow F; Yue Y; Martinez J; Deere JD; Longmate J; Herrmann A; Barry PA; Diamond DJ
J Virol; 2013 Feb; 87(3):1322-32. PubMed ID: 23152525
[TBL] [Abstract][Full Text] [Related]
9. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
10. Vaccine Development for Cytomegalovirus.
Inoue N; Abe M; Kobayashi R; Yamada S
Adv Exp Med Biol; 2018; 1045():271-296. PubMed ID: 29896672
[TBL] [Abstract][Full Text] [Related]
11. A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.
Choi KY; Root M; McGregor A
J Virol; 2016 Sep; 90(17):7902-19. PubMed ID: 27334585
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
[TBL] [Abstract][Full Text] [Related]
13. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.
Cardin RD; Bravo FJ; Pullum DA; Orlinger K; Watson EM; Aspoeck A; Fuhrmann G; Guirakhoo F; Monath T; Bernstein DI
Vaccine; 2016 Apr; 34(17):1993-9. PubMed ID: 26973071
[TBL] [Abstract][Full Text] [Related]
14. Immunization to prevent congenital cytomegalovirus infection.
Adler SP
Br Med Bull; 2013; 107():57-68. PubMed ID: 23954939
[TBL] [Abstract][Full Text] [Related]
15. Vaccines for cytomegalovirus.
Bernstein DI
Infect Disord Drug Targets; 2011 Oct; 11(5):514-25. PubMed ID: 22309618
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.
Choi KY; El-Hamdi NS; McGregor A
Vaccine; 2020 Feb; 38(10):2340-2349. PubMed ID: 32008881
[TBL] [Abstract][Full Text] [Related]
17. Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease.
Wang D; Fu TM
Curr Opin Virol; 2014 Jun; 6():13-23. PubMed ID: 24632198
[TBL] [Abstract][Full Text] [Related]
18. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
Pass RF
J Clin Virol; 2009 Dec; 46 Suppl 4(Suppl 4):S73-6. PubMed ID: 19647480
[TBL] [Abstract][Full Text] [Related]
19. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
20. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
Marshall BC; Adler SP
Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
